Legends
Figure 1. Kaplan-Meier analysis of event-free survival (EFS) and overall survival (OS) in the subgroup of pediatric NHL with genotype of the C677T polymorphism (n = 158). WT, wild genotype (CC); Mut, mutant genotype (CT/TT).
A. The 5-year EFS rate for CC, CT, and TT genotype was 68.0%, 87.7%, and 78.6%, respectively; CC/CT: P = 0.013; CC/TT: P = 0.633; CT/TT: P = 0.306;
B. Patients carrying mutant genotype had a significantly higher 5-year EFS rate than those with wild type (85.9% vs. 68.0%);
C-D. No significant difference was found in OS among different genotypes.
Figure 2. Kaplan-Meier analysis of event-free survival (EFS) and overall survival (OS) in the subgroup of pediatric BL and DLBCL with genotype of the C677T polymorphism (n = 81). WT, wild genotype (CC); Mut, mutant genotype (CT/TT).
A. The 5-year EFS rate for CC, CT, and TT genotype was 70.3%, 97.1%, and 85.7%, respectively; CC/CT: P = 0.004; CC/TT: P = 0.511; CT/TT: P = 0.210;
B. Patients carrying mutant genotype had a significantly higher 5-year EFS rate than those with wild type (95.1% vs. 70.3%);
C. The 5-year OS rate for CC, CT, and TT genotype was 81.9%, 100%, and 83.3%, respectively; CC/CT: P = 0.010; CC/TT: P = 0.779; CT/TT: P = 0.021;
D. Patients carrying mutant genotype had a significantly higher 5-year OS rate than those with wild type (97.4% vs. 81.9%).
Figure 3. Kaplan-Meier analysis of event-free survival (EFS) and overall survival (OS) in the whole group of pediatric NHL stratified by cancer type (A-B) and CNS involvement (C-D) (n = 374). CNS, central nervous system.
A. The 5-year EFS rate in ALCL (49.0%) was significantly lower than that in BL (79.0%; P = 0.021), DLBCL (87.4%; P=0.005), and LBL (76.7%; P = 0.006);
B. There was no significant difference in 5-year OS rate among the four NHL subtypes (BL, 85.9%; LBL 83.5%; ALCL,84.6%; DLBCL, 96.4%);
C. Patients with CNS involvement at diagnosis had a similar 5-year EFS rate with those without (74.7% vs. 69.0%);
D. Patients with CNS involvement at diagnosis had a significantly lower 5-year OS rate than those without (68.5% vs. 87.6%).
Figure 4. Kaplan-Meier analysis of event-free survival (EFS) and overall survival (OS) in the whole group of pediatric NHL stratified by stage (A-B) and risk (C-D) (n = 374). Early, stage I ⅈ advanced, stage III & IV.
A. The 5-year EFS rate of patients at advanced stage was significantly lower than that at early stage (89.0% vs. 72.2%);
B. The 5-year OS rate of patients at advanced stage was significantly lower than that at early stage (100% vs. 83.7%);
C. The 5-year EFS rate of intermediate-/high-risk patients was significantly lower than that of very low-/low-risk (91.3% vs. 70.8%);
D. The 5-year OS rate of intermediate-/high-risk patients was significantly lower than that of very low-/low-risk (98.3% vs. 83.0%).
Figure S1. Genetic variations of MTHFR C677T(A-C) and A1298C (D-F) were detected by PCR following Sanger sequencing.
Figure S2. Kaplan-Meier analysis of event-free survival (EFS) and overall survival (OS) in the subgroup of pediatric NHL with genotype of the A1298C polymorphism (n =154). WT, wild genotype (AA); Mut, mutant genotype (AC/CC). No significant difference was found in EFS and OS among different genotypes.
Figure S3. Kaplan-Meier analysis of event-free survival (EFS) and overall survival (OS) in the subgroup of pediatric BL and DLBCL with genotype of the A1298C polymorphism (n = 78). WT, wild genotype (AA); Mut, mutant genotype (AC/CC). No significant difference was found in EFS and OS among different genotypes.